Local drug maker TaiGen Biotechnology Co (太景生技) yesterday said that it expected to get permission from Chinese and Taiwanese health authorities to sell its new pneumonia drug in the first half of next year.
TaiGen’s oral formulation of nemonoxacin, an antibiotic, is used to cure community-acquired pneumonia, and might also prove effective in curing other diseases, such as diabetic foot, the company said.
The oral formulation of nemonoxacin was the first drug to be tested under the cross-strait Economic Cooperation Framework Agreement’s (ECFA) cooperation pact on medicine, which expedites the approval process by allowing TaiGen to conduct clinical trials in both Taiwan and China, and to submit applications to both governments using the same document.
“The large and fast-growing medical market in China can no longer be overlooked, which is the reason we tried to make use of the pact,” TaiGen CEO and chairman Hsu Ming-chu (許明珠) said at a press conference yesterday.
The market for both oral and intravenous formulations of nemonoxacin in China could amount to about 1 billion yuan (NT$4.88 billion) a year, the company said.
FIRST FOR TAIWAN
TaiGen’s drug is likely to be the first drug from Taiwan to meet the requirements to be registered as a category 1.1 new drug in China, and would enjoy a higher price premium, which was an incentive given by the Chinese government to encourage new drugs to debut in the country, Hsu said.
The oral formulation of nemo-noxacin was licensed to China-based Zhejiang Medicine Co (浙江醫藥集團) — which will be responsible for the marketing and manufacturing of the drug in China — for US$8 million and royalties of 7 percent to 11 percent on future sales of the drug.
TRIALS
The intravenous formulation of nemonoxacin is still in the second stage of clinical trials in China and Taiwan, TaiGen said.
Compared with existing drugs, nemonoxacin can minimize side effects and reduce the possibility of developing resistance to the drug, Hsu said.
Meanwhile, the Cayman Island-based company said it plans to launch an initial public offering in Taiwan by issuing 634 million shares on its Emerging Stock Market (興櫃市場) early next month. It is scheduled to move to the more active GRETAI Securities Market by the end of this year.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the